Last updated: August 26, 2026
Vidaza, the injectable formulation of azacitidine, is a mature oncology product with no meaningful U.S. brand exclusivity remaining. Celgene commercialized Vidaza after acquiring Pharmion, and Bristol Myers Squibb inherited the product through its 2019 Celgene acquisition. U.S. generic azacitidine injection approvals shifted the market from a branded specialty product to a multi-source hospital and oncology practice market. The principal commercial growth opportunity moved to Onureg, an oral azacitidine formulation approved in 2020, rather than Vidaza itself.
What is Vidaza and how is azacitidine used?
Vidaza is the brand name for azacitidine, a hypomethylating agent administered by subcutaneous or intravenous injection. The drug is used primarily in myelodysplastic syndromes and acute myeloid leukemia settings involving myelodysplasia-related changes.
| Attribute |
Vidaza |
| Active ingredient |
Azacitidine |
| Dosage form |
Injectable powder for suspension |
| Administration |
Subcutaneous or intravenous |
| Original innovator |
Pharmion |
| Later owner |
Celgene, then Bristol Myers Squibb |
| Initial FDA approval |
2004 |
| Main therapeutic area |
Myelodysplastic syndromes and AML-related settings |
| U.S. market status |
Generic competition |
| Related product |
Onureg oral azacitidine tablets |
| Biosimilar exposure |
None; azacitidine is a small molecule |
The FDA granted Vidaza accelerated approval in 2004 for treatment of myelodysplastic syndromes. The product later obtained expanded labeling based on confirmatory clinical evidence. The FDA label identifies azacitidine’s cytotoxic and epigenetic effects, including DNA hypomethylation and direct cytotoxicity in abnormal hematopoietic cells (U.S. Food and Drug Administration [FDA], 2023).
When did Vidaza lose exclusivity?
Vidaza lost practical U.S. market exclusivity after expiration of its principal patent estate and approval of generic azacitidine injection products.
The principal U.S. composition and use patent associated with Vidaza is U.S. Patent No. 6,887,855. Public patent records identify a 2022 expiration date for the patent, subject to applicable patent-term calculations and regulatory extensions. FDA Orange Book records and product-specific patent certifications determine the precise legal framework for each generic approval (FDA, 2024a; U.S. Patent and Trademark Office [USPTO], 2024).
Vidaza exclusivity timeline
| Date |
Event |
| 2004 |
FDA approves Vidaza for myelodysplastic syndromes |
| 2008 |
Celgene acquires Pharmion and obtains Vidaza |
| 2019 |
Bristol Myers Squibb announces acquisition of Celgene |
| 2020 |
FDA approves Onureg, oral azacitidine, for AML maintenance |
| 2022 |
Principal Vidaza patent protection reaches its reported expiration period |
| 2019-2024 |
Generic azacitidine injection products enter or expand in the U.S. market |
| 2024 onward |
Vidaza operates as a mature, largely genericized product |
Vidaza did not receive biologic-style reference-product exclusivity because azacitidine is a chemically synthesized small molecule. Its commercial protection depended on patents, regulatory exclusivity and manufacturing know-how.
What patents protect Vidaza?
Vidaza’s original protection centered on azacitidine composition, formulation and therapeutic-use claims. The most commercially important U.S. patent was U.S. Patent No. 6,887,855, associated with azacitidine treatment and product protection.
Patent protection was narrower than the full commercial opportunity. Generic manufacturers could challenge patents through abbreviated new drug applications and Paragraph IV certifications. Once core patents expired or ceased to block approval, generic azacitidine injection products could compete through the ANDA pathway.
What formulations are protected by Vidaza patents?
Vidaza is an injectable lyophilized powder requiring reconstitution before administration. The commercial barriers include:
- Stability of azacitidine after reconstitution.
- Control of degradation products.
- Sterile manufacturing and fill-finish operations.
- Packaging and storage requirements.
- Hospital and oncology-clinic preparation workflows.
- Consistent subcutaneous and intravenous dosing.
These factors can delay generic development, but they do not create durable exclusivity once the relevant patents expire. Formulation complexity is a manufacturing barrier, not a substitute for enforceable patent protection.
Onureg has a separate oral tablet formulation and a different clinical-use profile. Patents and regulatory protections for Onureg do not automatically protect Vidaza injection.
Which companies challenge Vidaza exclusivity?
Generic competition has included major injectable-drug manufacturers and specialty generic companies. Public FDA approval records identify generic azacitidine injection products from companies including Dr. Reddy’s Laboratories, Teva Pharmaceuticals and Hikma Pharmaceuticals, although product availability varies by strength, presentation, supplier and purchasing channel (FDA, 2024b).
The competitive field includes:
| Company category |
Examples |
Competitive role |
| Large generic manufacturers |
Teva, Dr. Reddy’s |
ANDA supply and hospital contracting |
| Injectable specialists |
Hikma and other sterile-injectable manufacturers |
Institutional supply and shortage management |
| Specialty distributors |
Oncology-focused distributors |
Practice and hospital channel access |
| Original sponsor |
Bristol Myers Squibb |
Residual Vidaza brand presence and related Onureg franchise |
A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework. Publicly available commercial data indicate that generic entry, rather than a later brand settlement, became the decisive factor in Vidaza’s U.S. erosion. No continuing settlement structure appears to preserve a material branded U.S. monopoly for Vidaza after the principal patent period.
What is the FDA regulatory status of Vidaza?
Vidaza remains an FDA-approved azacitidine injectable product. Generic versions are approved under the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.
The regulatory distinction between Vidaza and Onureg is material:
| Product |
Form |
FDA pathway |
Principal use |
| Vidaza |
Injectable azacitidine |
Original NDA and generic ANDAs |
MDS and related hematologic disease |
| Onureg |
Oral azacitidine tablets |
Separate NDA |
Continued AML treatment after intensive chemotherapy and remission or remission with incomplete blood-count recovery |
Onureg is not an interchangeable dosage-form substitute for Vidaza. Physicians select between products based on treatment phase, disease status, tolerability, administration burden, reimbursement and clinical evidence.
How did Vidaza revenue develop?
Vidaza reached maturity before generic competition. Celgene reported Vidaza as part of its hematology and oncology portfolio, with annual revenue generally in the mid-hundreds of millions of dollars during the late 2010s. Public company reporting did not always present a consistent global product-level series, and subsequent Bristol Myers Squibb reporting placed greater emphasis on larger products such as Revlimid, Eliquis, Opdivo and Pomalyst.
The financial trajectory can be summarized as follows:
| Period |
Financial position |
Main driver |
| 2004-2008 |
Launch and adoption |
New therapy for MDS |
| 2008-2015 |
Strong specialty-product growth |
Celgene ownership, expanding hematology use |
| 2016-2019 |
Mature branded revenue |
Established treatment standards and repeat use |
| 2020 |
Transition period |
Generic pressure begins; Onureg launches |
| 2021-2024 |
Rapid branded erosion |
Multi-source generic supply and price competition |
Celgene’s acquisition of Pharmion for approximately $2.9 billion in 2008 reflected the strategic value of Vidaza and Pharmion’s hematology pipeline. By the time Bristol Myers Squibb acquired Celgene for approximately $74 billion in equity value in 2019, Vidaza was a mature asset rather than a primary transaction driver. The strategic value rested more heavily on Revlimid, Pomalyst, Abraxane, the immuno-oncology portfolio and pipeline assets (Celgene Corporation, 2018; Bristol Myers Squibb, 2020).
What caused Vidaza’s revenue decline?
Vidaza’s revenue decline followed the standard lifecycle of a specialty small molecule:
- Core patent protection expired.
- FDA-approved generic injections entered the market.
- Hospital and oncology practices used competitive sourcing.
- Payers and group purchasing organizations increased price pressure.
- The branded product lost formulary and purchasing priority.
- Bristol Myers Squibb shifted commercial emphasis toward higher-growth assets.
Injectable oncology products can retain some brand demand because of physician familiarity, supply reliability and procurement preferences. These factors may support residual sales, but they rarely prevent substantial price erosion after generic entry.
The decline also reflects a product-mix shift. Patients requiring continued AML therapy after remission may be treated with Onureg rather than injectable Vidaza when clinically appropriate. This creates franchise continuity for Bristol Myers Squibb but does not preserve Vidaza’s original revenue base.
How does Vidaza compare with Onureg?
Onureg has a stronger post-Vidaza commercial profile because it addresses a different treatment phase and offers oral administration. Its value proposition is based on maintenance treatment after initial intensive chemotherapy, not replacement of injectable azacitidine in every patient.
| Factor |
Vidaza |
Onureg |
| Route |
Injection |
Oral |
| Treatment setting |
MDS and AML-related injectable therapy |
AML maintenance |
| FDA approval year |
2004 |
2020 |
| Generic competition |
Yes |
Patent and regulatory protection remain more relevant |
| Administration burden |
Clinic or supervised preparation |
Oral outpatient use |
| Revenue outlook |
Declining mature product |
Higher strategic value within azacitidine franchise |
| Substitution |
Not automatically interchangeable |
Not automatically interchangeable |
Onureg’s approval was based substantially on the QUAZAR AML-001 study, which showed improved relapse-free and overall survival in selected AML patients receiving oral azacitidine maintenance after intensive chemotherapy (Wei et al., 2020). The clinical differentiation reduces direct substitution with Vidaza, although both products contain azacitidine.
What is the Orange Book status of Vidaza?
Vidaza’s Orange Book status reflects a reference-listed drug with generic azacitidine injection competition. The practical importance of legacy Orange Book patents has declined as principal patent terms have expired and ANDA products have entered the market.
Key Orange Book considerations include:
- The reference listed drug designation for Vidaza.
- Listed patents associated with azacitidine.
- Paragraph IV certifications filed by generic applicants.
- The 30-month stay mechanism when applicable litigation is timely filed.
- Generic approval dates and therapeutic-equivalence listings.
- Product availability by strength and package configuration.
Orange Book status is product-specific. A patent listed for Vidaza injection does not necessarily cover Onureg tablets, and a patent covering Onureg’s method of use does not necessarily block generic Vidaza injection.
What generic launch risks exist for Vidaza?
The U.S. generic launch risk is high because the principal patent barriers have passed and multiple manufacturers have entered the category. The main remaining risks are commercial rather than legal.
Commercial risks
- Price compression from multi-source supply.
- Reduced branded reimbursement.
- Hospital purchasing consolidation.
- Contract losses to lower-cost suppliers.
- Temporary shortages that can shift share between manufacturers.
- Lower physician incentive to prescribe the branded product.
- Limited ability to sustain premium pricing.
Manufacturing and supply risks
Azacitidine is sensitive to handling and degradation. Sterile injectable production requires validated processes, regulatory compliance and reliable active pharmaceutical ingredient supply. These constraints can produce intermittent shortages or uneven generic availability. Supply constraints may preserve some Vidaza demand temporarily, but they do not restore durable exclusivity.
Does Vidaza face biosimilar competition?
No. Vidaza is a small-molecule drug and does not face biosimilar competition under the Public Health Service Act. Its competitors are generic azacitidine products approved through ANDAs.
This distinction affects litigation, substitution and pricing:
| Issue |
Vidaza |
| Competition pathway |
ANDA generics |
| Biosimilar pathway |
Not applicable |
| Interchangeability standard |
Pharmaceutical equivalence and therapeutic equivalence |
| Main legal framework |
Hatch-Waxman |
| Primary erosion mechanism |
Generic entry and contracting |
What licensing deals affected Vidaza?
The principal transaction affecting Vidaza was the acquisition of Pharmion by Celgene in 2008. Pharmion developed and commercialized Vidaza before the acquisition. Bristol Myers Squibb later acquired Celgene, transferring ownership of the product.
No major recent third-party licensing transaction has changed Vidaza’s competitive position. The asset is now managed as part of a broader hematology portfolio rather than as a standalone growth platform.
What patent litigation affects Vidaza?
Vidaza’s principal litigation exposure occurred during the period when generic manufacturers sought ANDA approval and patent holders attempted to delay or restrict entry. The legal risk centered on:
- Validity of the listed azacitidine patents.
- Infringement by proposed generic formulations.
- Paragraph IV certifications.
- The scope of method-of-use claims.
- Any pediatric or regulatory exclusivity extensions.
After the core patent term ended and generic products became available, continuing litigation had limited ability to protect a long-term branded market monopoly. Current commercial risk is therefore driven mainly by generic supply, contracting and reimbursement.
How strong is the Vidaza patent estate?
Vidaza’s current patent estate is weak as a commercial defense in the United States. The product had meaningful historical protection, but the core patent term has expired and generic entrants are established.
| Patent-strength factor |
Assessment |
| Core composition or use protection |
Expired or no longer commercially blocking |
| Formulation protection |
Limited ability to block standard injectable competition |
| Method-of-use claims |
Narrower and dependent on labeled use |
| Regulatory exclusivity |
Expired |
| Generic entry barriers |
Low to moderate |
| Manufacturing complexity |
Moderate |
| Current U.S. brand moat |
Low |
Geographic protection varies. Patent expiration, generic approval and reimbursement conditions differ across the United States, Europe, Japan and emerging markets. In markets where injectable generic penetration is slower, Vidaza may retain brand sales longer. The global trend remains toward generic substitution.
What is the outlook for Vidaza revenue?
Vidaza revenue should be treated as declining or residual in the United States. The product can retain value through established clinical use, supply reliability, international sales and situations where clinicians prefer the branded presentation. Those factors are insufficient to support the late-life revenue levels achieved before generic entry.
Bristol Myers Squibb’s azacitidine franchise outlook depends more on Onureg than Vidaza. For investors and licensing teams, Vidaza is primarily a mature cash-flow asset with low patent optionality, while Onureg represents the more relevant product for lifecycle management, label expansion and commercial forecasting.
Key Takeaways
- Vidaza is injectable azacitidine, first approved by the FDA in 2004.
- Celgene acquired the product through Pharmion, and Bristol Myers Squibb later acquired Celgene.
- The principal U.S. patent protection reached expiration in the 2022 period.
- Teva, Dr. Reddy’s, Hikma and other manufacturers created generic competition.
- Vidaza has no biosimilar risk because it is a small molecule.
- U.S. branded revenue is structurally impaired by generic substitution.
- Injectable manufacturing complexity may affect supply, but it does not recreate patent exclusivity.
- Onureg, oral azacitidine, is the more strategically important product in the franchise.
- Current Vidaza value is concentrated in residual brand demand, international markets and supply reliability.
- The patent estate is weak for defending a long-term U.S. monopoly.
FAQs
Is Vidaza still sold in the United States?
Vidaza remains an FDA-approved reference product, but generic azacitidine injection products compete in the U.S. market. Actual brand availability can vary by distributor, hospital contract and supply conditions.
Can generic azacitidine replace Vidaza automatically?
Generic azacitidine products may be therapeutically equivalent when listed by FDA as substitutable for the relevant reference product and presentation. Institutional substitution remains subject to pharmacy, formulary and procurement rules.
Is Onureg the same drug as Vidaza?
Both products contain azacitidine, but Onureg is an oral tablet and Vidaza is an injectable formulation. They have different dosing, administration, clinical settings and FDA-approved indications.
What is the biggest remaining barrier to generic Vidaza?
The principal remaining barrier is sterile injectable manufacturing and supply reliability. Patent protection is no longer the primary obstacle in the U.S. market.
Does Vidaza have patent protection outside the United States?
Patent rights are jurisdiction-specific. Some countries may have had later-expiring patents, supplementary protection certificates or slower generic uptake, but the product’s global commercial position is that of a mature therapy facing broad generic competition.
References
-
Bristol Myers Squibb. (2020). 2020 annual report. Bristol Myers Squibb.
-
Celgene Corporation. (2018). 2018 annual report. Celgene Corporation.
-
U.S. Food and Drug Administration. (2023). Vidaza (azacitidine) prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). Patent Center and patent term information for U.S. Patent No. 6,887,855. U.S. Department of Commerce.
-
Wei, A. H., Döhner, H., Pochet, L., et al. (2020). Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. New England Journal of Medicine, 383(26), 2526-2537.
